Read more

December 23, 2019
1 min read
Save

Vitamin D supplementation linked with reduced proteinuria in patients with CKD

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Supplementary vitamin D in low doses may reduce proteinuria in patients with chronic kidney disease, according to results of a nonblinded, non-placebo-controlled study.

The 24-week study included 60 patients with CKD who received a stable dose of either angiotensin receptor blocker (ARB) or angiotensin-converting enzyme inhibitor (ACEI) for more than 1 month. Patients had an average estimated glomerular filtration rate of more than 15 mL/min. Researchers assigned these patients into either a vitamin D group or a control group. The primary endpoint of the study was to find a definitive percentage of urine protein/creatinine ratio (uPCR) change in patients with CKD.

“[T]he severity of proteinuria was found to decrease after calcitriol treatment in patients with CKD who received doses of an [renin-angiotensin-aldosterone system] RAAS inhibitor,” Chia-Chao Wu, PhD, of the department of internal medicine at Tri-Service General Hospital in the National Defense Medical Center in TaiPei, Taiwan, and colleagues, wrote.

Researchers found the uPCR in the vitamin D group decreased significantly at 8 and 16 weeks, with a result of 2.02 ± 0.25 g/g to 1.35 ± 0.17 g/g at the end of the 24 weeks. A positive correlation was found between reduction in uPCR in the vitamin D group at 24 weeks and baseline serum 25-(OH) D levels.

According to the researchers, findings from the study were consistent with results of other studies that showed vitamin D therapy exerts similar antiproteinuric effects in patients with CKD treated with a RAAS inhibitor.

“In conclusion, supplementary low-dose active vitamin D could significantly reduce the severity of proteinuria among patients with CKD,” the researchers wrote. They added, “Therefore, we suggest that prospective long-term and larger studies should be conducted to determine whether earlier commencement of vitamin D therapy in patients with CKD would be beneficial and whether the therapy can delay CKD progression.” –by Erin T. Welsh